Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 18;144(3):334-338.
doi: 10.1182/blood.2024024526.

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Gilles Crochet  1 , Gloria Iacoboni  2   3 , Audrey Couturier  4 , Emmanuel Bachy  5 , Josu Iraola-Truchuelo  3 , Thomas Gastinne  6 , Guillaume Cartron  7 , Tom Fradon  8 , Bastien Lesne  8 , Mi Kwon  9 , Romain Gounot  10 , Nuria Martínez-Cibrian  11 , Cristina Castilla-Llorente  12 , Pau Abrisqueta  2   3 , Manuel Guerreiro  13 , Clémentine Sarkozy  14 , Jose María Aspa-Cilleruelo  15 , Vincent Camus  16 , Stéphanie Guidez  17 , Adrien Chauchet  18 , Eric Deconinck  18 , Krimo Bouabdallah  19 , Francesc Bosch  2   3 , Pere Barba  2   3 , Franck Morschhauser  20 , Roch Houot  4
Affiliations
Free article

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Gilles Crochet et al. Blood. .
Free article

Abstract

In this retrospective study, chimeric antigen receptor T cells remained effective in patients with relapsed/refractory large B-cell lymphoma after prior exposure to bispecific antibodies (BsAbs) targeting different antigens. These results are relevant to clinical practice, particularly given the increasing use of BsAbs in earlier treatment lines.

PubMed Disclaimer

Comment in

References

Substances